Skip to main content

Jaguar Health, Inc.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

JAGX$0.44+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

Six Months Ended
June 30,
(in thousands) · 2025 · 2024
Cash flows from operating activities
Net comprehensive loss$(21,441)$(18,872)
Adjustments to reconcile net comprehensive loss to net cash used in operating activities:
Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option2,4113,831
Loss (gain) on extinguishment of debt1,822(1,245)
Depreciation and amortization expenses957948
Stock-based compensation, vested and released restricted stock units, and exercised stock options580964
Amortization of operating lease - right-of-use asset145221
Share in joint venture's loss7546
Amortization of debt issuance costs, debt discount, and non-cash interest expense—274
Shares issued in exchange for services—9
Changes in assets and liabilities
Accounts receivable354668
Other receivable(13)146
Inventory(374)(367)
Prepaid expenses and other current assets(775)(2,665)
Other assets106736
Accounts payable1,285(875)
Accrued liabilities1,581374
Deferred revenue(85)808
Operating lease liability(137)(218)
Total cash used in operating activities(13,509)(15,217)
Cash flows from investing activity
Purchase of equipment—(16)
Total cash used in investing activity—(16)
Cash flows from financing activities
Proceeds from Convertible Notes3,445—
Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $47 and $109 in 2025 and 2024, respectively3,25024,008
Proceeds from issuance of shares to third party investors1,309—
Proceeds from issuance of common shares in exchange for License Agreement—1,150
Payment of Tempesta Note(50)(50)
Payment of Convertible Notes(20)—
Repayment of insurance financing(313)(266)
Total cash provided by financing activities7,62124,842
Effects of foreign exchange rate changes on assets and liabilities93(29)
Net increase (decrease) in cash(5,795)9,580
Cash at beginning of the period8,0026,469
Cash at end of the period$2,207$16,049

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

Six Months Ended
June 30,
2025 · 2024
Supplemental schedule of cash flow information
Cash paid for interest$9$13
Supplemental schedule of non-cash financing and investing activities
Preferred stock issued to Iliad in exchange of notes payable and accrued interest$4,800$—
Preferred stock issued in exchange of another class of preferred stock$2,485$1,999
Preferred stock issued to Streeterville in exchange for notes payable and accrued interest$2,250$4,485
Common shares issued to Irving in exchange of notes payable and accrued interest$1,210$—
Common stock issued to Iliad in exchange for notes payable and accrued interest$1,100$836
Common stock issued to note holders in exchange of convertible notes payable and accrued interest$866$—
First Insurance Financing$681$519
Recognition of operating lease - right-of-use asset and operating lease liability$341$219
Common stock issued to Streeterville in exchange for notes payable and accrued interest$315$166
Umbrella Insurance Financing$—$52

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.